Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
Titel:
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
Auteur:
Charehbili, A. van de Ven, S. Smit, V.T.H.B.M. Meershoek-Klein Kranenbarg, E. Hamdy, N.A.T. Putter, H. Heijns, J.B. van Warmerdam, L.J.C. Kessels, L. Dercksen, M. Pepels, M.J. Maartense, E. van Laarhoven, H.W.M. Vriens, B. Wasser, M.N. van Leeuwen-Stok, A.E. Liefers, G.J. van de Velde, C.J.H. Nortier, J.W.R. Kroep, J.R.